These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35492562)

  • 41. Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.
    Simões MF; Pereira A; Cardoso S; Cadonau S; Werner K; Pinto RMA; Simões S
    Mol Pharm; 2020 Feb; 17(2):554-568. PubMed ID: 31774685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
    Newman A; Reutzel-Edens SM; Zografi G
    J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs.
    Wei Y; Ling Y; Su M; Qin L; Zhang J; Gao Y; Qian S
    Chem Pharm Bull (Tokyo); 2018; 66(12):1114-1121. PubMed ID: 30504628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crystallization kinetics and molecular dynamics of binary coamorphous systems of nimesulide and profen analogs.
    Zhang J; Shi Q; Qu T; Zhou D; Cai T
    Int J Pharm; 2021 Dec; 610():121235. PubMed ID: 34743960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Freeze Dried Quetiapine-Nicotinamide Binary Solid Dispersions: A New Strategy for Improving Physicochemical Properties and Ex Vivo Diffusion.
    Ali AM; Al-Remawi MM
    J Pharm (Cairo); 2016; 2016():2126056. PubMed ID: 28042494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced Dissolution Rate of Tadalafil Nanoparticles Prepared by Sonoprecipitation Technique: Optimization and Physicochemical Investigation.
    Teymouri Rad R; Mortazavi SA; Vatanara A; Dadashzadeh S
    Iran J Pharm Res; 2017; 16(4):1335-1348. PubMed ID: 29721025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eutectic Mixture Formation and Relaxation Dynamics of Coamorphous Mixtures of Two Benzodiazepine Drugs.
    Valenti S; Cazorla C; Romanini M; Tamarit JL; Macovez R
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.
    Alhalaweh A; Bergström CAS; Taylor LS
    J Control Release; 2016 May; 229():172-182. PubMed ID: 27006280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determination of the Optimal Molar Ratio in Amino Acid-Based Coamorphous Systems.
    Liu J; Rades T; Grohganz H
    Mol Pharm; 2020 Apr; 17(4):1335-1342. PubMed ID: 32119557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of acidifier and solubilizer in tadalafil solid dispersion to enhance the in vitro dissolution and oral bioavailability in rats.
    Choi JS; Kwon SH; Lee SE; Jang WS; Byeon JC; Jeong HM; Park JS
    Int J Pharm; 2017 Jun; 526(1-2):77-87. PubMed ID: 28450170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
    Andrews GP; AbuDiak OA; Jones DS
    J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of induction methods for supersaturation: Amorphous dissolution versus solvent shift.
    Plum J; Bavnhøj CG; Eliasen JN; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2020 Jul; 152():35-43. PubMed ID: 32376371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
    Yin LF; Huang SJ; Zhu CL; Zhang SH; Zhang Q; Chen XJ; Liu QW
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization.
    Renuka ; Singh SK; Gulati M; Narang R
    Pharm Dev Technol; 2017 Feb; 22(1):13-25. PubMed ID: 26708555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.
    Ruponen M; Kettunen K; Santiago Pires M; Laitinen R
    Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33514009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.